Gerald Chan - 01 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Director
Signature: /s/ David Watson, attorney-in-fact for Gerald Chan
Issuer symbol: APLS
Transactions as of: 01 Jan 2024
Net transactions value: +$344,075
Form type: 4
Filing time: 02 Jan 2024, 16:10:50 UTC
Previous filing: 04 Jan 2023
Next filing: 03 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+3,341	+41%	$0.000000	11,438	01 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$344,075	+5,748		$59.86	5,748	01 Jan 2024	Common Stock	5,748	$59.86	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
F2	This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.